CUMBERLAND PHARMACEUTICALS ANNOUNCES NATIONAL CALL TO PRESENT AN UPDATE ON ITS IFETROBAN DMD PROGRAM
PR Newswire•19/10/2026•16:06 ET
1
Key Highlights
- ➤Cumberland schedules October 26 update on ifetroban DMD cardiomyopathy program
- ➤National webcast and conference call begin October 26 at 4:30 p.m. Eastern Time
- ➤Ifetroban is being evaluated for cardiomyopathy associated with Duchenne muscular dystrophy
CUMBERLAND PHARMACEUTICALS ANNOUNCES NATIONAL CALL TO PRESENT AN UPDATE ON ITS IFETROBAN DMD PROGRAM PR Newswire
NASHVILLE, Tenn., Oct. 19, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation-driven biopharmaceutical company advancing new therapies that address significant unmet medical needs, announced today that it will provide an update on its ifetroban product candidate in development as a potential treatment for the cardiomyopathy associated with Duchenne muscular dystrophy ("DMD").
Get started
Create a free account to read the full story.